Pulmonary arterial hypertension (PAH) is an increasingly understood disease, with the genetics and pathophysiology mapped out to the extent that new therapies are emerging.1 The epidemiology, however, ...

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension ...

Introduction Fluoroquinolones can cause severe collagen-associated adverse effects, potentially impacting the pulmonary ...

Pathophysiology is the study of functional changes that happen ... Other conditions that commonly occur along with heart failure include diabetes, COPD, sleep apnea, and kidney disease. Heart failure ...

Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications.

Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

The diagnosis of COPD can be frustrating for both the patient and the physician, especially when a patient is identified as having the frequent-exacerbation phenotype. Counseling these patients is ...

5.3 Potential interplay of HDAC3 and NLRP3 in IPF pathogenesis Scutellaria (the principal active constituent in brevicaffin) has been demonstrated to mitigate inflammation and epithelial–mesenchymal ...

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

The current pathophysiology of COPD encompasses three main characteristics: emphysema, chronic bronchitis and small airway disease. Macrophages and neutrophils are implicated in this process ...